


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (II), or a prodrug thereof, or a pharmaceutically acceptable salt of the compound or the prodrug:

[Formula 1]



where A_1 is C- X_1 or N;

Q_1 is $-A_2=A_3-$, or a heteroatom selected from -O-, -S-, and $-N(R_{10})-$; Q_2 is $-A_4=A_5-$, or a heteroatom selected from -O-, -S-, and $-N(R_{10})-$; provided that Q_1 and Q_2 are not heteroatoms at the same time;

A_2 is C- X_2 or N, A_3 is C- X_3 or N, A_4 is C- X_4 or N, and A_5 is C- X_5 or N;

R_{10} is a hydrogen atom, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-6} alkylcarbonyl or aryl; the aryl being optionally

substituted by one or more substituents selected from a halogen atom, C₁₋₆alkyl, and C₁₋₆alkoxy;

X₁, X₂, X₃, X₄ and X₅ are each independently selected from the group consisting of a hydrogen atom, hydroxy, a halogen atom, cyano, hydroxyaminocarbonyl, hydroxyamidino, nitro, amino, amidino, guanidino, C₁₋₆alkylamino, diC₁₋₆alkylamino, C₁₋₆alkylamidino, diC₁₋₆alkylamidino, C₁₋₆alkylguanidino, diC₁₋₆alkylguanidino, C₁₋₆alkylthio, C₁₋₆alkylsulfo, C₁₋₆alkylsulfonyl, C₁₋₆alkylphosphono, diC₁₋₆alkylphosphono, C₁₋₆alkyl, C₁₋₆alkoxy, C₃₋₉cycloalkyl, C₃₋₉cycloalkoxy, C₂₋₇alkenyl, C₂₋₇alkynyl, C₁₋₆alkylcarbonyl, C₁₋₆alkoxycarbonyl (the above 19 groups may be substituted by one or more substituents selected from a halogen atom, hydroxy, aryl, heteroaryl, and cyano), aryl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy, heteroarylcarbonyl, and arylC₁₋₆alkyloxy (the above 7 groups may be substituted by one or more substituents selected from a halogen atom, C₁₋₆alkyl, and C₁₋₆alkoxy); or

X₁ and X₂, X₂ and X₃, X₃ and X₄, and X₄ and X₅, together with the carbon atoms to which they are bound, form a saturated or unsaturated 5- to 7-membered carbocyclic ring, or a saturated or unsaturated 5- to 7-membered heterocyclic ring containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom;

Y is selected from the group consisting of C₁₋₆alkyl, C₃₋₉cycloalkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₁₋₆alkylcarbonyl, C₁₋₆alkoxycarbonyl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, C₁₋₆alkoxy, C₂₋₇alkenyloxy, C₂₋₇alkynyloxy, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl {the above 15 groups may be substituted by one or more substituents selected from a saturated or unsaturated 3- to 7-membered carbocyclyl, a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom, a halogen atom, hydroxy, C₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, aminoC₁₋₆alkoxy, N-C₁₋₆alkylaminoC₁₋₆alkoxy, N,N-diC₁₋₆alkylaminoC₁₋₆alkoxy, amino, C₁₋₆alkylamino, hydroxyC₁₋₆alkylamino, C₁₋₆alkoxyC₁₋₆alkylamino, aminoC₁₋₆alkylamino, diC₁₋₆alkylamino, bis(hydroxyC₁₋₆alkyl)amino, bis(C₁₋₆alkoxyC₁₋₆alkyl)amino, bis(aminoC₁₋₆alkyl)amino, amidino, C₁₋₆alkylamidino, diC₁₋₆alkylamidino, guanidino, C₁₋₆alkylguanidino, diC₁₋₆alkylguanidino, cyano, carboxyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, C₁₋₆alkylphosphono, and diC₁₋₆alkylphosphono}, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino (the above 2 groups may be substituted by one or more substituents selected from a saturated or unsaturated 3- to 7-membered carbocyclyl, a saturated or unsaturated 3- to

7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom, a halogen atom, hydroxy, C₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, aminoC₁₋₆alkoxy, N-C₁₋₆alkylaminoC₁₋₆alkoxy, N,N-diC₁₋₆alkylaminoC₁₋₆alkoxy, amino, C₁₋₆alkylamino, hydroxyC₁₋₆alkylamino, C₁₋₆alkoxyC₁₋₆alkylamino, aminoC₁₋₆alkylamino, diC₁₋₆alkylamino, bis(hydroxyC₁₋₆alkyl)amino, bis(C₁₋₆alkoxyC₁₋₆alkyl)amino, bis(aminoC₁₋₆alkyl)amino, amidino, C₁₋₆alkylamidino, diC₁₋₆alkylamidino, guanidino, C₁₋₆alkylguanidino, diC₁₋₆alkylguanidino, cyano, carboxyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, C₁₋₆alkylphosphono, and diC₁₋₆alkylphosphono), a halogen atom, nitro, cyano, carboxyl, and a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom (the heterocyclyl may be substituted by one or more substituents selected from hydroxy, C₁₋₆alkyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, and oxo);

Z is selected from the group consisting of a hydrogen atom, hydroxy, C₁₋₆alkyl, C₃₋₉cycloalkyl {the above 2 groups may be substituted by one or more substituents selected from a saturated or unsaturated 3- to 7-membered carbocyclyl


(the carbocyclyl group may be substituted by one or more substituents selected from C_{1-6} alkyl, hydroxy C_{1-6} alkyl, and C_{1-6} alkoxy C_{1-6} alkyl), a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom (the heterocyclyl group may be substituted by one or more substituents selected from C_{1-6} alkyl, hydroxy C_{1-6} alkyl, and C_{1-6} alkoxy C_{1-6} alkyl), a halogen atom, hydroxy, C_{1-6} alkoxy, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkoxy, hydroxy C_{1-6} alkoxy C_{1-6} alkoxy, amino C_{1-6} alkoxy, N- C_{1-6} alkylamino C_{1-6} alkoxy, N,N-di C_{1-6} alkylamino C_{1-6} alkoxy, amino, C_{1-6} alkylamino, hydroxy C_{1-6} alkylamino, C_{1-6} alkoxy C_{1-6} alkylamino, amino C_{1-6} alkylamino, di C_{1-6} alkylamino, bis(hydroxy C_{1-6} alkyl)amino, bis(C_{1-6} alkoxy C_{1-6} alkyl)amino, bis(amino C_{1-6} alkyl)amino, cyano, carboxyl, C_{1-6} alkoxycarbonyl, aryloxy carbonyl, carbamoyl, C_{1-6} alkylcarbamoyl, di C_{1-6} alkylcarbamoyl{the above 2 groups may be substituted by one or more substituents selected from a halogen atom, hydroxy, cyano and amino), phosphono, C_{1-6} alkylphosphono, di C_{1-6} alkylphosphono, sulfonic acid, and C_{1-6} alkylsulfo}, and -OR₁ and -NR₁R₂;

R₁ and R₂ are each dependently selected from the group consisting of a hydrogen atom, C_{1-6} alkyl,

C₁₋₆alkylcarbonyl, and a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom (the above 3 groups may be substituted by one or more substituents selected from a saturated or unsaturated 3- to 7-membered carbocyclyl, a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom, a halogen atom, hydroxy, C₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, aminoC₁₋₆alkoxy, N-C₁₋₆alkylaminoC₁₋₆alkoxy, N,N-diC₁₋₆alkylaminoC₁₋₆alkoxy, amino, C₁₋₆alkylamino, hydroxyC₁₋₆alkylamino, C₁₋₆alkoxyC₁₋₆alkylamino, aminoC₁₋₆alkylamino, diC₁₋₆alkylamino, bis(hydroxyC₁₋₆alkyl)amino, bis(C₁₋₆alkoxyC₁₋₆alkyl)amino, bis(aminoC₁₋₆alkyl)amino, cyano, carboxyl, C₁₋₆alkoxycarbonyl, aryloxy carbonyl, phosphono, C₁₋₆alkylphosphono, diC₁₋₆alkylphosphono, sulfonic acid, and C₁₋₆alkylsulfo); or R₁ and R₂, together with the nitrogen atoms to which they are bound, form a saturated or unsaturated 5- to 7-membered heterocyclic ring containing one nitrogen atom and optionally further containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; and


L is selected from the formula:

[Formula 2]



2. (Original) The compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to claim 1, wherein the compound is represented by the formula (I):

[Formula 3]



where A₁, A₂, A₃, A₄, A₅, L, Y, and Z are as defined in claim 1.

3. (Currently Amended) The compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to claim 1-~~or 2~~, wherein Z is a hydrogen atom, C₁₋₆alkyl, C₃₋₉cycloalkyl, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, cyanoC₁₋₆alkyl, pyridylC₁₋₆alkyl, dihydroxyC₁₋₆alkyl, trihydroxyC₁₋₆alkyl, morpholinoC₁₋₆alkyl, (N,N-diC₁₋₆alkylamino)C₁₋₆alkyl, or (N,N-bis(hydroxyC₁₋₆alkyl)amino)C₁₋₆alkyl.

4. (Original) The compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to claim 3, wherein Z is a hydrogen atom, methyl, ethyl, cyclopropyl, cyclopentyl, 2-hydroxyethyl, 2-(2-hydroxyethoxy)ethyl, 2-methoxyethyl, 2-cyanoethyl, 4-pyridylmethyl, 1-methoxybut-2-yl, 2,3-dihydroxyprop-1-yl, 1,3-dihydroxyprop-2-yl, 1,3-dihydroxy-2-hydroxymethylprop-2-yl, 2-morpholinoethyl, 1-hydroxyprop-2-yl, 1-hydroxy-3-methylbut-2-yl, 2-(N,N-dimethylamino)ethyl, 2-(N,N-bis(2-hydroxyethyl)amino)ethyl, 2,4-dihydroxybutyl, 2,3,4-trihydroxybutyl, 2,3,4,5-tetrahydroxypentyl, or 2,3,4,5,6-pentahydroxyhexyl.

5. (Currently Amended) The compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to ~~any one of claims~~ claim 1 to 4, wherein Y is a halogen atom, cyano, C₁₋₆alkyl, haloC₁₋₆alkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₁₋₆alkoxy, C₃₋₉cycloalkylC₁₋₆alkoxy, C₂₋₇alkynyloxy, or haloC₁₋₆alkoxy.

6. (Original) The compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to claim 5, wherein Y is chloro, bromo,

cyano, methyl, trifluoromethyl, ethyl, n-propyl, i-propyl, ethynyl, methoxy, trifluoromethoxy, cyclopropylmethoxy, 2-butyne-1-yloxy, or 2-chloroethoxy.

7. (Currently Amended) The compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to claim 1-~~or 2~~, wherein

A₁ is C-X₁ or N, A₂ is C-X₂ or N, A₃ is C-X₃ or N, A₄ is C-X₄ or N, and A₅ is C-X₅ or N;

X₁, X₂, X₃, X₄ and X₅ are each independently selected from a hydrogen atom, a halogen atom, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, C₁₋₆alkylthio, and haloC₁₋₆alkylthio; or

X₁ and X₂, X₂ and X₃, X₃ and X₄, and X₄ and X₅, together with the carbon atoms to which they are bound, form a cyclohexane ring, a cyclopentane ring, a benzene ring, a pyridine ring, a pyrimidine ring, a 1,4-dioxane ring, a 1,3-dioxolane ring, a pyrrole ring, an imidazole ring, a thiazole ring, or a furan ring.

8. (Original) The compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to claim 7, wherein

X_1 , X_2 , X_3 , X_4 and X_5 are each independently selected from a hydrogen atom, fluoro, chloro, bromo, methyl, ethyl, t-butyl, i-propyl, methoxy, i-propoxy, trifluoromethyl, trifluoromethoxy, methylthio, and trifluoromethylthio; or

X_1 and X_2 , together with the carbon atoms to which they are bound, form a cyclohexane ring;

X_1 and X_2 , together with the carbon atoms to which they are bound, form a pyridine ring;

X_2 and X_3 , together with the carbon atoms to which they are bound, form a 1,4-dioxane ring; or

X_2 and X_3 , together with the carbon atoms to which they are bound, form a cyclopentane ring.

9. (Original) The compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to claim 8, wherein A_1 is C- X_1 or N, A_2 is C- X_2 , A_3 is C- X_3 , A_4 is C- X_4 , and A_5 is C- X_5 .

10. (Original) The compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to claim 8, wherein A_1 is C- X_1 , A_2 is C- X_2 or N, A_3 is C- X_3 , A_4 is C- X_4 , and A_5 is C- X_5 .

11. (Original) The compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to claim 8, wherein A_1 is C- X_1 , A_2 is C- X_2 , A_3 is C- X_3 or N, A_4 is C- X_4 , and A_5 is C- X_5 .

12 (Currently Amended) A pharmaceutical composition containing the compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to ~~any one of claims~~ claim 1 to 11, as an active ingredient.

13. (Currently Amended) An angiogenesis inhibitor containing the compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to ~~any one of claims~~ claim 1 to 11, as an active ingredient.

14. (Currently Amended) An agent for treatment and prevention of a disease involving angiogenesis, said agent containing the compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to ~~any one of claims~~ claim 1 to 11, as an active ingredient.

15. (Original) The agent for treatment and prevention, according to claim 14, wherein said disease involving angiogenesis is a cancerous disease.

16. (Original) The agent for treatment and prevention, according to claim 15, wherein said cancerous disease is solid tumor.

17. (Currently Amended) An agent for treatment and prevention of metastasis of solid tumor, said agent containing the compound, or the prodrug thereof, or the pharmaceutically acceptable salt of the compound or the prodrug, according to ~~any one of claims claim 1 to 11~~, as an active ingredient.